Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Peter Ganly

PositionClinical Senior Lecturer
DepartmentDepartment of Pathology and Biomedical Science (Christchurch)
QualificationsBM BCh(Oxford) MA PhD(Cambridge) FRACP FRCPA
Research summaryCancer

Research

Dr Ganly's expertise and interests include the diagnosis and management of malignant haematological diseases, stem cell transplantation and clinical research.

Publications

Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet-Loiseau, H., Masszi, T., Viterbo, L., … Ganly, P., … Moreau, P. (2020). c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. european journal of haematology, 105(1), 35-46. doi: 10.1111/ejh.13405

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & Macpherson, S. A. (2019). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal, 49, 598-606. doi: 10.1111/imj.14155

Mascarenhas, J., Virtgaym, E., Stal, M., Blacklock, H., Gerds, A. T., Mesa, R., Ganly, P., … Moshier, E. (2018). Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: A sponsor-independent international study. Annals of Hematology, 97(8), 1369-1374. doi: 10.1007/s00277-018-3309-6

Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., … Ganly, P., … Harrison, C. N. (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematology, 4(5), e225-e236. doi: 10.1016/S2352-3026(17)30027-3

Avet-Loiseau, H., Bahlis, N. J., Chng, W.-J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., … Richardson, P. G. (2017). Ixazomib significantly prolongs progression-free survival in high-rick relapse/refractory myeloma patients. Blood, 130(24), 2610-2618. doi: 10.1182/blood-2017-06-791228

Journal - Research Article

Di Bacco, A., Bahlis, N. J., Munshi, N. C., Avet-Loiseau, H., Masszi, T., Viterbo, L., … Ganly, P., … Moreau, P. (2020). c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. european journal of haematology, 105(1), 35-46. doi: 10.1111/ejh.13405

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & Macpherson, S. A. (2019). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal, 49, 598-606. doi: 10.1111/imj.14155

Mascarenhas, J., Virtgaym, E., Stal, M., Blacklock, H., Gerds, A. T., Mesa, R., Ganly, P., … Moshier, E. (2018). Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: A sponsor-independent international study. Annals of Hematology, 97(8), 1369-1374. doi: 10.1007/s00277-018-3309-6

Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., … Ganly, P., … Harrison, C. N. (2017). Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematology, 4(5), e225-e236. doi: 10.1016/S2352-3026(17)30027-3

Avet-Loiseau, H., Bahlis, N. J., Chng, W.-J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., … Richardson, P. G. (2017). Ixazomib significantly prolongs progression-free survival in high-rick relapse/refractory myeloma patients. Blood, 130(24), 2610-2618. doi: 10.1182/blood-2017-06-791228

Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V. I., Paschka, P., … Ganly, P., … Campbell, P. J. (2017). Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics, 49, 332-340. doi: 10.1038/ng.3756

Grigg, A., Butcher, B., Khodr, B., Bajel, A., Hertzberg, M., Patil, S., D'Souza, A., Ganly, P., … on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG). (2017). An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: Results of a phase II prospective trial. Bone Marrow Transplantation, 52, 1288-1293. doi: 10.1038/bmt.2017.108

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., … Ganly, P., … Campbell, P. J. (2016). Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374(23), 2209-2221. doi: 10.1056/NEJMoa1516192

Bolli, N., Li, Y., Sathiaseelan, V., Raine, K., Jones, D., Ganly, P., … Munshi, N. C. (2016). A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer Journal, 6(9), e467. doi: 10.1038/bcj.2016.72

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., … Ganly, P., … for the TOURMALINE-MM1 Study Group. (2016). Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 374, 1621-1634. doi: 10.1056/NEJMoa1516282

Mant, S., Taylor, G., Dutton, D., Butler, A., Browett, P., & Ganly, P. (2015). Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic leukemia: A series of six cases. Leukemia & Lymphoma, 56(3), 774-778. doi: 10.3109/10428194.2014.927460

Ganly, P., Cole, S., Trengrove, A., & Butler, A. (2014). Outcomes of allogeneic haematopoietic stem cell transplants at a small New Zealand centre: Does size matter? Internal Medicine Journal, 44(7), 683-689. doi: 10.1111/imj.12456

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Nivison-Smith, I., Dodds, A. J., Doocey, R., Ganly, P., Gibson, J., Ma, D. D. F., … Bradstock, K. F. (2011). Allogeneic haemopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: Factors associated with improved survival outcome. Leukemia & Lymphoma, 52(9), 1727-1735. doi: 10.3109/10428194.2011.582201

Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., . . ., Ganly, P. S., & et al (2010). Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28(10), 1756-1765. doi: 10.1200/JCO.2009.26.4556

Kim, D.-W., Banavali, S. D., Bunworasate, U., Goh, Y.-T., Ganly, P., Huang, H., … Wong, R. (2010). Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy group. Leukemia Research, 34(11), 1459-1471. doi: 10.1016/j.leukres.2010.03.033

Marr, H., McDonald, E.-J., Merriman, E., Smith, M., Mangos, H., Stoddart, C., & Ganly, P. (2009). Successful treatment of transplant-associated microangiopathy with rituximab [Clinical correspondence]. New Zealand Medical Journal, 122(1292). Retrieved from http://journal.nzma.org.nz/journal/122-1292/3534/content.pdf

Hernandez, E., Ganly, P., Charu, V., DiBenedetto, J., Tomita, D., Lillie, T., … ARANESP 20030232 Study Group. (2009). Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Current Medical Research & Opinion, 25(9), 2109-2120. doi: 10.1185/03007990903084164

Ganly, P. S., Keeman, H., Spearing, R. L., Smith, M. P., Patton, N., Merriman, E. G., & Gibbons, S. S. (2008). Written advice can provide a safe and acceptable alternative to new patient assessment for selected referrals to haematologists. Medical Journal of Australia, 188(1), 9-12.

Sanders, J., Pithie, A., Ganly, P., Surgenor, L., Wilson, R., Merriman, E., … Chambers, S. (2008). A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. Journal of Antimicrobial Chemotherapy, 62(4), 809-815. doi: 10.1093/jac/dkn284

Ganly, P., Hanrahan, V., Baker, B., & Romeril, K. (2007). Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. American Journal of Hematology, 82, 80-82.

Ganly, P., & Spearing, R. (2006). Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefit [Editorial]. New Zealand Medical Journal, 119(1246). Retrieved from http://journal.nzma.org.nz/journal/119-1246/2335/content.pdf

Gough, S. M., Benjes, S. M., McDonald, M., Heaton, D., Ganly, P., & Morris, C. M. (2006). Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia. Cancer Genetics & Cytogenetics, 165, 36-40.

Gough, S. M., Benjes, S. M., McDonald, M. A., Heaton, D., Ganly, P., & Morris, C. M. (2006). Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemia. Cancer Genetics & Cytogenetics, 165(1), 36-40. doi: 10.1016/j.cancergencyto.2005.08.008

Chambers, S. T., Sanders, J., Patton, W. N., Ganly, P., Birch, M., Crump, J. A., & Spearing, R. L. (2005). Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: Results from a prospective randomized controlled trial. Journal of Hospital Infection, 61, 53-61.

Ganly, P., McDonald, M., Spearing, R., & Morris, C. M. (2004). Constitutional t(5;7)(q11;p15) rearranged to acquire monosomy 7q and trisomy 1q in a patient with myelodysplastic syndrome transforming to acute myelocytic leukemia. Cancer Genetics & Cytogenetics, 149(2), 125-130.

Ganly, P. S., Walker, L. C., & Morris, C. M. (2004). Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leukemia & Lymphoma, 45(1), 1-10.

Carradice, D., Austin, N., Bayston, K., & Ganly, P. S. (2002). Successful treatment of acute promyelocytic leukaemia during pregnancy. Clinical & Laboratory Haematology, 24, 307-311.

Walker, L. C., Campbell, H. J., Corbett, R., Spearing, R. L., Heaton, D. C., Macdonald, D. H., Morris, C. M., & Ganly, P. S. (2002). A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. British Journal of Haematology, 117(4), 878-881. doi: 10.1046/j.1365-2141.2002.03512.x

Mullin, J. L., Brennan, S., Ganly, P. S., & George, P. M. (2002). Fibrinogen Hillsborough: A Novel γ309Gly→ Asp Dysfibrinogen. Blood, 99, 3597-3610.

Jackson, G., Taylor, P., Smith, G. M., Marcus, R., Smith, A., Chu, P., … Ganly, P. S., … Wilson, M. P. (2001). A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine abd granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. British Journal of Haematology, 112(1), , 127-137. doi: 10.1046/j.1365-2141.2001.02551.x

Ganly, P. S., & Beard, M. (2001). Osteoclasts in Paget's disease of bone. British Journal of Haematology, 113, 259.

Whittle, A. T., Davis, M., Shovlin, C. L., Ganly, P. S., Haslett, C., & Greening, A. P. (2001). Alveolar macrophage activity and the pulmonary complications of haematopoietic stem cell transplantation. Thorax, 56, 941-946.

^ Top of page

Journal - Research Other

Ganly, P., Downing, J., Stiven, P., Frizelle, F., & Badami, K. (2011). Clinical and serological diagnoses of a patient with vancomycin-induced thrombocytopenia [Letter to the editor]. Transfusion Medicine, 21(2), 137-139. doi: 10.1111/j.1365-3148.2010.01052.x

Ganly, P., Saleem, M., Marr, H., Burt, M., Florkowski, C., & Williamson, A. (2008). Not walking or communicating: Is all well? [Case report]. Lancet, 372(9655), 2086. doi: 10.1016/S0140-6736(08)61870-X

More publications...